The firm attributes its lower revenue projections to conservative estimates for Levemir and Victoza, two of Novo Nordisk's products. With an impressive gross profit margin of 84.66% and a P/E ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

Novo Nordisk is actively defending its older diabetes medication, Victoza. This week, the company submitted a citizen petition to the U.S. Food and Drug Association (FDA) requesting that the FDA ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

Novo Nordisk's (CO:NOVOb) top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a... Investing.com – Denmark stocks were lower after ...

The firm attributes its lower revenue projections to conservative estimates for Levemir and Victoza, two of Novo Nordisk's products. With an impressive gross profit margin of 84.66% and a P/E ratio of ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...